Cyfuse Biomedical K.K. (JP:4892)
:4892
Top Page
Cyfuse Biomedical K.K.
(4892)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥589.00
▼(-0.17% Downside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by weak financial performance—deep losses and ongoing negative free cash flow—despite a strong revenue rebound and manageable leverage. Technicals are moderately supportive with improving short-to-mid-term trend and constructive momentum, while valuation remains constrained by unprofitability and no dividend yield provided.
Positive Factors
Proprietary Bio-3D printing tech
Cyfuse's scaffold-free Bio-3D Printer and Kenzan method represent a distinctive platform technology in regenerative medicine. As a core proprietary capability, it creates a durable technical barrier, underpins product development and research collaborations, and supports long-term differentiation.
Negative Factors
Persistent negative cash flow
Operating and free cash flows remain deeply negative, forcing reliance on external capital to sustain operations. Continued cash burn limits runway, risks dilution or costly financing, and constrains the company’s ability to scale activities or invest in commercialization without securing durable funding sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Bio-3D printing tech
Cyfuse's scaffold-free Bio-3D Printer and Kenzan method represent a distinctive platform technology in regenerative medicine. As a core proprietary capability, it creates a durable technical barrier, underpins product development and research collaborations, and supports long-term differentiation.
Read all positive factors
Cyfuse Biomedical K.K. (4892) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.05B
Dividend YieldN/A
Average Volume (3M)50.89K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth56.17%
EPS Growth-11.63%
CountryJP
Employees21
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-12.09
Shares Outstanding9,970,400
10 Day Avg. Volume43,580
30 Day Avg. Volume50,893
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.88
Price to Sales (P/S)22.48
P/FCF Ratio-8.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cyfuse Biomedical K.K. Business Overview & Revenue Model
Company Description
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and...
How the Company Makes Money
null...
Cyfuse Biomedical K.K. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.82M | 231.00M | 54.45M | 61.11M | 374.48M | 708.25M |
| Gross Profit | -3.23M | 78.40M | 1.56M | -378.00K | 223.93M | 568.20M |
| EBITDA | -883.27M | -792.68M | -860.12M | -659.31M | -370.81M | 89.07M |
| Net Income | -827.55M | -763.84M | -872.24M | -589.21M | -473.96M | 142.91M |
Balance Sheet | ||||||
| Total Assets | 3.23B | 4.27B | 3.52B | 4.21B | 4.82B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.70B | 3.73B | 3.05B | 3.87B | 4.44B | 2.41B |
| Total Debt | 766.00M | 1.31B | 852.80M | 913.00M | 857.79M | 569.06M |
| Total Liabilities | 901.89M | 1.51B | 975.60M | 1.01B | 1.05B | 746.12M |
| Stockholders Equity | 2.33B | 2.76B | 2.54B | 3.20B | 3.77B | 1.90B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -581.93M | -768.16M | -581.77M | -631.87M | 161.54M |
| Operating Cash Flow | 0.00 | -534.79M | -760.55M | -562.30M | -403.60M | 161.54M |
| Investing Cash Flow | 0.00 | -397.56M | -8.64M | -19.47M | -430.67M | -50.58M |
| Financing Cash Flow | 0.00 | 1.26B | -52.01M | 18.24M | 2.66B | 229.21M |
Cyfuse Biomedical K.K. Technical Analysis
Neutral
590.00
Price Trends
633.64
Negative
613.75
Negative
635.01
Negative
Market Momentum
-6.92
Negative
48.84
Neutral
67.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4892, the sentiment is Neutral. The current price of 590 is below the 20-day moving average (MA) of 610.95, below the 50-day MA of 633.64, and below the 200-day MA of 635.01, indicating a neutral trend. The MACD of -6.92 indicates Negative momentum. The RSI at 48.84 is Neutral, neither overbought nor oversold. The STOCH value of 67.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4892.
Cyfuse Biomedical K.K. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥6.31B | 9.13 | ― | 3.00% | 2.21% | -22.75% | |
64 Neutral | ¥6.20B | 11.64 | ― | 3.21% | 4.25% | ― | |
53 Neutral | ¥9.28B | -13.67 | -90.96% | ― | 243.16% | -23.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥6.05B | -6.80 | ― | ― | 56.17% | -11.63% | |
43 Neutral | ¥5.83B | -0.95 | ― | ― | -50.27% | -3.33% | |
41 Neutral | ¥4.99B | -2.01 | ― | ― | ― | 47.43% |
* Healthcare Sector Average
JP:4892
Cyfuse Biomedical K.K.
607.00
-388.00
-38.99%
JP:4597
Solasia Pharma KK
34.00
2.00
6.25%
JP:4539
Nippon Chemiphar Co., Ltd.
1,718.00
280.87
19.54%
JP:4582
Symbio Pharmaceuticals Limited
98.00
-52.00
-34.67%
JP:4883
Modalis Therapeutics Corporation
54.00
-23.00
-29.87%
JP:7079
WDB coco Co., Ltd.
2,622.00
-486.82
-15.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.